Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15150992 | 1.00 | MTNR1A (0.36) | MTNR1AMTNR1BSLC6A2SLC6A4TP53 | |
| SCHEMBL19291602 | 1.00 | MTNR1A (0.36) | MTNR1AMTNR1BSLC6A2SLC6A4TP53 | |
| SCHEMBL15150975 | 1.00 | MTNR1A (0.36) | MTNR1AMTNR1BSLC6A2SLC6A4TP53 | |
| SCHEMBL15150990 | 1.00 | MTNR1A (0.36) | MTNR1AMTNR1BSLC6A2SLC6A4TP53 | |
| SCHEMBL15150998 | 1.00 | MTNR1A (0.36) | MTNR1AMTNR1BSLC6A2SLC6A4TP53 | |
| SCHEMBL15150983 | 0.99 | MTNR1A (0.36) | MTNR1AMTNR1BKDM4ENSD2ALDH1A1 | |
| SCHEMBL15150974 | 0.99 | MTNR1A (0.36) | MTNR1AMTNR1BKDM4ENSD2ALDH1A1 | |
| SCHEMBL4568996 | 0.88 | GPBAR1 (0.44) | MTNR1AMTNR1BTP53DRD2ACE2 | |
| SCHEMBL4568998 | 0.88 | GPBAR1 (0.44) | MTNR1AMTNR1BTP53DRD2ACE2 | |
| SCHEMBL4568997 | 0.88 | GPBAR1 (0.44) | MTNR1AMTNR1BTP53DRD2ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3210966-A1 | ALKOXYPHENYLPROPYLAMINES FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Acucela, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | MTNR1A 89/4885MTNR1B 85/4885SLC6A2 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.